Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)
Abstract Background KIR/HLA mismatch in hematopoietic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia (AML), was related to decreased recurrence rates, improved engraftment, and a reduction in graft-versus-host disease, according to recent research (GVHD). Unce...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | BMC Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12865-023-00548-1 |
| _version_ | 1827917044705656832 |
|---|---|
| author | Tahereh Bakhtiari Mohammad Ahmadvand Marjan Yaghmaie Alireza Sadeghi Seied Asadollah Mousavi Tahereh Rostami Mazdak Ganjalikhani-Hakemi |
| author_facet | Tahereh Bakhtiari Mohammad Ahmadvand Marjan Yaghmaie Alireza Sadeghi Seied Asadollah Mousavi Tahereh Rostami Mazdak Ganjalikhani-Hakemi |
| author_sort | Tahereh Bakhtiari |
| collection | DOAJ |
| description | Abstract Background KIR/HLA mismatch in hematopoietic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia (AML), was related to decreased recurrence rates, improved engraftment, and a reduction in graft-versus-host disease, according to recent research (GVHD). Uncertainty exists about the impact of KIR/HLA mismatch on haploidentical-HSCTs treated with post-transplant cyclophosphamide (PTCy). We attempted to analyze the effects of KIR/HLA mismatch on clinical outcomes on transplant outcomes using the cohort of 54 AML patients who received a haplo-HSCT with PTCy. Results In contrast to KIR/HLA match, our findings showed that donor KIR/HLA mismatch was substantially associated with superior OS (HR, 2.92; (P = 0.04)). Moreover, donor KIR/HLA mismatch (KIR2DS1D/C2+ R and KIR2DS2D/C1+ R mismatch versus KIR2DL1D/C2− R mm, KIR2DL2/3D/C1− R mm and KIR3DL1D/Bw4− mm) was correlated with the improvements in OS (HR, 0.74; P = 0.085) and activating. KIR/HLA mismatch versus KIR/HLA match was significantly correlated with improvements in OS (HR, .46; P = 0.03) and inhibitory. KIR/HLA mismatch versus KIR/HLA match was enhancement in the OS (HR, .93; P = 0.06). Despite a higher rate of aGvHD (grade I-IV) in the patients with KIR/HLA mismatch compared to KIR/HLA matched (57% vs. 33% (p = 0.04). However, the KIR/HLA mismatch group saw a decreased relapse rate (3.2% vs. 23%, p = 0.04). Conclusion This analysis shows the significance of KIR/HLA Incompatibility, other clinical variables like CMV, the relationship between donor/recipient and donor age, and the relationship between donor/recipient and donor age in the haplo-donor selection process. It also suggests that KIR and HLA mismatching between donor and recipient could be routinely performed for haplo-donor selection and may improve clinical outcomes after haplo-HSCTs with PTCy. |
| first_indexed | 2024-03-13T03:23:10Z |
| format | Article |
| id | doaj.art-6a112b111e154687bb440c2aa30301fb |
| institution | Directory Open Access Journal |
| issn | 1471-2172 |
| language | English |
| last_indexed | 2024-03-13T03:23:10Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Immunology |
| spelling | doaj.art-6a112b111e154687bb440c2aa30301fb2023-06-25T11:13:04ZengBMCBMC Immunology1471-21722023-06-0124111310.1186/s12865-023-00548-1Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)Tahereh Bakhtiari0Mohammad Ahmadvand1Marjan Yaghmaie2Alireza Sadeghi3Seied Asadollah Mousavi4Tahereh Rostami5Mazdak Ganjalikhani-Hakemi6Department of Immunology, School of Medicine, Isfahan University of Medical SciencesCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical SciencesHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical SciencesDepartment of Internal Medicine, Faculty of Medicine, Isfahan University of Medical SciencesCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical SciencesHematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical SciencesDepartment of Immunology, School of Medicine, Isfahan University of Medical SciencesAbstract Background KIR/HLA mismatch in hematopoietic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia (AML), was related to decreased recurrence rates, improved engraftment, and a reduction in graft-versus-host disease, according to recent research (GVHD). Uncertainty exists about the impact of KIR/HLA mismatch on haploidentical-HSCTs treated with post-transplant cyclophosphamide (PTCy). We attempted to analyze the effects of KIR/HLA mismatch on clinical outcomes on transplant outcomes using the cohort of 54 AML patients who received a haplo-HSCT with PTCy. Results In contrast to KIR/HLA match, our findings showed that donor KIR/HLA mismatch was substantially associated with superior OS (HR, 2.92; (P = 0.04)). Moreover, donor KIR/HLA mismatch (KIR2DS1D/C2+ R and KIR2DS2D/C1+ R mismatch versus KIR2DL1D/C2− R mm, KIR2DL2/3D/C1− R mm and KIR3DL1D/Bw4− mm) was correlated with the improvements in OS (HR, 0.74; P = 0.085) and activating. KIR/HLA mismatch versus KIR/HLA match was significantly correlated with improvements in OS (HR, .46; P = 0.03) and inhibitory. KIR/HLA mismatch versus KIR/HLA match was enhancement in the OS (HR, .93; P = 0.06). Despite a higher rate of aGvHD (grade I-IV) in the patients with KIR/HLA mismatch compared to KIR/HLA matched (57% vs. 33% (p = 0.04). However, the KIR/HLA mismatch group saw a decreased relapse rate (3.2% vs. 23%, p = 0.04). Conclusion This analysis shows the significance of KIR/HLA Incompatibility, other clinical variables like CMV, the relationship between donor/recipient and donor age, and the relationship between donor/recipient and donor age in the haplo-donor selection process. It also suggests that KIR and HLA mismatching between donor and recipient could be routinely performed for haplo-donor selection and may improve clinical outcomes after haplo-HSCTs with PTCy.https://doi.org/10.1186/s12865-023-00548-1KIR/HLA mismatchKIR/HLA matchAcute myeloid leukemiaPost-transplant cyclophosphamideHaploidentical TransplantHSCT |
| spellingShingle | Tahereh Bakhtiari Mohammad Ahmadvand Marjan Yaghmaie Alireza Sadeghi Seied Asadollah Mousavi Tahereh Rostami Mazdak Ganjalikhani-Hakemi Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML) BMC Immunology KIR/HLA mismatch KIR/HLA match Acute myeloid leukemia Post-transplant cyclophosphamide Haploidentical Transplant HSCT |
| title | Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML) |
| title_full | Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML) |
| title_fullStr | Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML) |
| title_full_unstemmed | Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML) |
| title_short | Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML) |
| title_sort | investigation of kir hla relationship and other clinical variables after t cell replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia aml |
| topic | KIR/HLA mismatch KIR/HLA match Acute myeloid leukemia Post-transplant cyclophosphamide Haploidentical Transplant HSCT |
| url | https://doi.org/10.1186/s12865-023-00548-1 |
| work_keys_str_mv | AT taherehbakhtiari investigationofkirhlarelationshipandotherclinicalvariablesaftertcellrepletehaploidenticalbonemarrowtransplantationinpatientswithacutemyeloidleukemiaaml AT mohammadahmadvand investigationofkirhlarelationshipandotherclinicalvariablesaftertcellrepletehaploidenticalbonemarrowtransplantationinpatientswithacutemyeloidleukemiaaml AT marjanyaghmaie investigationofkirhlarelationshipandotherclinicalvariablesaftertcellrepletehaploidenticalbonemarrowtransplantationinpatientswithacutemyeloidleukemiaaml AT alirezasadeghi investigationofkirhlarelationshipandotherclinicalvariablesaftertcellrepletehaploidenticalbonemarrowtransplantationinpatientswithacutemyeloidleukemiaaml AT seiedasadollahmousavi investigationofkirhlarelationshipandotherclinicalvariablesaftertcellrepletehaploidenticalbonemarrowtransplantationinpatientswithacutemyeloidleukemiaaml AT taherehrostami investigationofkirhlarelationshipandotherclinicalvariablesaftertcellrepletehaploidenticalbonemarrowtransplantationinpatientswithacutemyeloidleukemiaaml AT mazdakganjalikhanihakemi investigationofkirhlarelationshipandotherclinicalvariablesaftertcellrepletehaploidenticalbonemarrowtransplantationinpatientswithacutemyeloidleukemiaaml |